Opendata, web and dolomites

SDS-OmiProbe SIGNED

Revolutionary opto-biological methodology for aggressive HER2 cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SDS-OmiProbe project word cloud

Explore the words cloud of the SDS-OmiProbe project. It provides you a very rough idea of what is the project "SDS-OmiProbe" about.

gap    organization    volume    detects    cancer    diagnostic    tests    trials    expensive    projected    efficacy    breast    worth    die    transparency    laboratory    fail    biomarker    market    carries    diagnosis    realization    diagnosed    global    vivo    breakthrough    marker    performed    markers    14    probe    business    methodology    tip    worldwide    million    biopsies    cell    companion    cancers    billion    rapid    trend    revolutionary    soa    tools    health    tool    resolution    her2    opportunity    sds       according    world    causes    followed    levels    omiprobe    mortality    quantitative    tumours    essence    500    drugs    biopsy    tissue    close    landscape    invasive    extracting    women    subject    optimization    therapy    optic    opto    discordance    independent    report    morbidity    samples    accuracy    realize    concentration    cellular    biological    striking    device    instant    approximately    clinical    compelling    annually    single    disease    cells   

Project "SDS-OmiProbe" data sheet

The following table provides information about the project.

Coordinator
SDS OPTIC SPOLKA AKCYJNA 

Organization address
address: KONSTANTYNOW 1F
city: LUBLIN
postcode: 20 708
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Poland [PL]
 Project website https://sdsoptic.pl/
 Total cost 3˙985˙000 €
 EC max contribution 3˙985˙000 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2017
 Duration (year-month-day) from 2017-12-01   to  2021-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SDS OPTIC SPOLKA AKCYJNA PL (LUBLIN) coordinator 3˙985˙000.00

Map

 Project objective

According to World Health Organization, cancer is one of the leading causes of morbidity and mortality worldwide, with approximately 14 million new cases per year. Breast cancer is the most common cancer among women, and is considered the second most common cancer overall. Each year about 1.7 million new cases are diagnosed worldwide and over 500,000 women die from the disease.

Current diagnosis methods of cancers fail to deliver objective results. Diagnosis require extracting tissue samples via invasive and expensive biopsy, followed by laboratory analysis, which are subject to significant levels of discordance.

SDS Optic presents a revolutionary opto-biological methodology that allows for instant cellular processes studies including in-vivo cancer diagnosis with single-cell resolution. SDS-OmiProbe detects presence and measures concentration levels of the HER2 cancer cells in breast tumours. It is a breakthrough device that carries the potential to address the challenges of SoA cancer markers diagnosis and biopsies. In essence, it is a laboratory test at the tip of a probe, but with greater accuracy, efficacy and quantitative results. SDS-OmiProbe may also be used as a companion diagnostic tool for targeted therapy and targeted therapy drugs.

There is compelling evidence that our novel SDS-OmiProbe is addressing a rapid growth trend in a high volume market. Based on Transparency Market Research Report the OmiProbe target market of HER2- biomarker tests is projected to be worth $4.6 billion, with 7.5 million HER2 marker tests performed annually worldwide.

In order to close the striking gap in the landscape of currently available cancer diagnostic and targeted therapy tools, and to realize the significant global business opportunity the objective of this project is optimization of the SDS-OmiProbe device, followed by realization of independent clinical trials and dissemination of the results.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SDS-OMIPROBE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SDS-OMIPROBE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

PD_Pal (2019)

Palliative care in Parkinson’s disease

Read More  

PREMSTEM (2020)

Brain injury in the premature born infant: stem cell regeneration research network

Read More